ARS Pharmaceuticals (SPRY) Cash from Operations (QoQ) (2020 - 2026)

ARS Pharmaceuticals (SPRY) Cash from Operations (QoQ) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 ARS Pharmaceuticals 595.78 Mn 394.81 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -3.36%
Dec 31, 2025 7.57%
Sep 30, 2025 -18.83%
Jun 30, 2025 2.82%
Mar 31, 2025 -197.00%
Dec 31, 2024 390.34%
Sep 30, 2024 -98.75%
Jun 30, 2024 -8.48%
Mar 31, 2024 61.45%
Dec 31, 2023 -36.37%
Sep 30, 2023 23.43%
Jun 30, 2023 -34.11%
Mar 31, 2023 39.36%
Dec 31, 2022 -260.74%
Sep 30, 2022 18.53%
Jun 30, 2022 -0.71%
Mar 31, 2022 -124.83%
Dec 31, 2021 245.90%
Sep 30, 2021 -35.26%
Jun 30, 2021 -15.85%